Page 1

0 ( Mark One ) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31 , 2020 Or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 ( d ) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number : 000-26727 BioMarin Pharmaceutical Inc. ( Exact name of registrant as specified in its charter ) Delaware ( State or other jurisdiction of incorporation or organization ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 Form 10 - K 770 Lindaro Street San Rafael ( Address of principal executive offices ) Title of each class Common Stock , par value $ .001 California 68-0397820 ( I.R.S. Employer Identification No. ) 94901 ( Zip Code ) ( 415 ) 506-6700 ( Registrant's telephone number , including area code ) Securities registered pursuant to Section 12 ( b ) of the Act : Trading Symbol ( s ) BMRN Securities registered under Section 12 ( g ) of the Act : None Name of each exchange on which registered The Nasdaq Global Select Market No No 风 Indicate by check mark if the registrant is a well - known seasoned issuer , as defined in Rule 405 of the Securities Act . Yes > Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15 ( d ) of the Act . Yes Indicate by check mark whether the registrant ( 1 ) has filed all reports required to be filed by Section 13 or 15 ( d ) of the Securities Exchange Act of 1934 during the preceding 12 months ( or for such shorter period that the registrant was required to file such reports ) , and ( 2 ) has been subject to such filing requirements for the past 90 days . Yes No No Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S - T ( § 232.405 of this chapter ) during the preceding 12 months ( or for such shorter period that the registrant was required to submit such files ) . Yes > Indicate by check mark whether the registrant is a large accelerated filer , an accelerated filer , a non - accelerated filer , a smaller reporting company , or an emerging growth company . See the definitions of " large accelerated filer , " " accelerated filer , " " smaller reporting company , " and " emerging growth company " in Rule 12b - 2 of the Exchange Act . Large accelerated filer Accelerated filer Non - accelerated filer 1 Smaller reporting company Emerging Growth company 0 0 If an emerging growth company , indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13 ( a ) of the Exchange Act . Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404 ( b ) of the Sarbanes - Oxley Act ( 15 U.S.C. 7262 ( b ) ) by the registered public accounting firm that prepared or issued its audit report . Yes Indicate by check mark whether the registrant is a shell company ( as defined in Rule 12b - 2 of the Act . ) Yes No > The aggregate market value of the voting and non - voting common stock held by non - affiliates of the registrant as of June 30 , 2020 was $ 13.9 billion , based on the closing price reported for such date on the Nasdaq Global Select Market . As of February 12 , 2021 , the registrant had 181,829,680 shares of common stock , par value $ 0.001 , outstanding . No Documents Incorporated by Reference : Specified portions of the registrant's definitive proxy statement for the registrant's 2021 annual meeting of stockholders , which will be filed with the Commission no later than 120 days after the end of the registrant's fiscal year ended December 31 , 2020 , are incorporated by reference under Part III of this Annual Report on Form 10 - K .